The study on the treatment of chronic kidney disease iii in Dagle net was successfully terminated early
-
Last Update: 2021-03-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
March 30, AstraZenecom announced the early termination of the Phase III DAPA-CKD study on the treatment of chronic kidney disease in Dagley net, as recommended by the Independent Data Monitoring Board.The DAPA-CKD study included 4,245 patients with stage II-IV chronic kidney disease with elevated urinary albumin excretion rates in 21 countries worldwide (not considering whether type 2 diabetes is associated with it), primarily assessing the differences in efficacy and safety given to Dagley net 10 mg and placebo on a standard basis. The compound endpoint of the study was a deterioration or death of kidney function, defined as a continuous decline of more than 50% of eGFR, progressing to end-stage renal disease, cardiovascular death, and kidney death. Details of the study will be released at a medical conference soon, and AstraZeneca will immediately begin communication with regulators around the world to discuss the application for a listing.On September 16, 2019, the FDA granted Dagly net fast track eligibility to delay progression in renal failure and prevent cardiovascular and kidney death risk in patients with chronic kidney disease. A listing application for Dagrid's net treatment for heart failure has been submitted and has been reviewed as a priority by the FDA, as well as in the European Union and several regions. (Medical Rubik's Cube)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
